Pfizer and Calibr Collaborate on Heart Failure Drugs

US drug firm Pfizer is linking with non-profit organization The California Institute for Biomedical Research (Calibr) to develop new heart failure treatments.

Calibr said its antibody fusion technology offers a proprietary, modular approach to developing long-acting biotherapeutics based on peptide and protein agonists and antagonists.

Under terms of the deal, Pfizer can obtain an exclusive license to certain antibody-based therapeutic agents following Phase 1 clinical trials that Calibr will perform. If Pfizer takes the license, then it would be responsible for further development and commercialization.

The agreement also gives Pfizer a right of first negotiation for additional agents being developed by Calibr.

Full financial details were not disclosed, but Calibr will receive an upfront payment and additional milestone payments up to the completion of Phase 1 studies. If Pfizer decides to take a license, then Calibr will get further fees and milestone payments plus any tiered royalties on net sales.

Peter Schultz, chairman and president of Calibr, said heart disease continued to be a major medical burden on society as the development of new therapies has been challenging.

The move comes just days after Pfizer announced it was investing $46 million into four early-stage research companies as part of an expansion of its R&D strategy. The companies are exploring conditionally active biologics (CABs), immuno-oncology, neurodegenerative technologies and gene therapy.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.